Roche licensed SIM-0600, a preclinical trispecific T-cell engager from Simcere Zaiming Pharmaceutical, in a potential $1.53 billion transaction. The agreement centers on a CD79a/CD19/CD3-targeting format designed to drive T-cell-mediated killing of B-cell malignancies while managing cytokine-release toxicity associated with earlier TCE approaches. Simcere is eligible for an upfront fee plus development, regulatory, and commercial milestones.